ReviewDiabetes & metabolism journal2021
Management of Cardiovascular Risk in Perimenopausal Women with Diabetes.
Review in Diabetes & metabolism journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 16 citations in OpenAlex.
- Global Burden of Key Components of Cardiovascular-Kidney-Metabolic Syndrome Among Women of Reproductive Age, 1990-2021.Journal of evidence-based medicine · 2026Article
- Insulin resistance and uric acid-related metabolic disturbances jointly identify individuals at high risk of advanced cardiovascular-kidney-metabolic syndrome: a population-based study.Frontiers in nutrition · 2026Article
- Impact of sex and menopausal hormonal therapy on cardiovascular diseases in people with diabetes or prediabetes.Scientific reports · 2025Article
- Vitamin D alleviates obesity-related metabolic abnormalities by modulating the gut microbiota in older female mice on a high-fat diet.Frontiers in cellular and infection microbiology · 2025Article
- Article
- Analysis of Exosomal miRNA and Hepatic mRNA Expression in the Dysregulation of Insulin Action in Perimenopausal Mice.Journal of diabetes research · 2025Article
- Nurse-led intervention in the management of patients with cardiovascular diseases: a brief literature review.BMC nursing · 2024Article
- Sex differences in the correlation between lipids related to cardiovascular risk factors and small dense LDL particles in patients with type 2 diabetes.Archives of endocrinology and metabolism · 2024Article
- Determination of the Level of Cardiovascular Risk in 172,282 Spanish Working Women.Diagnostics (Basel, Switzerland) · 2023Article
- Comparison of seven surrogate insulin resistance indexes for predicting the prevalence of carotid atherosclerosis in normal-weight individuals.Frontiers in public health · 2023Article
- Traditional and Emerging Sex-Specific Risk Factors for Cardiovascular Disease in Women.Reviews in cardiovascular medicine · 2022Review
- Reproductive Life Span and Severe Hypoglycemia Risk in Postmenopausal Women with Type 2 Diabetes Mellitus.Diabetes & metabolism journal · 2022Article
- Global hotspots and prospects of perimenopausal depression: A bibliometric analysisFrontiers in psychiatry · 2022Review
- Gestational Diabetes Mellitus: Diagnostic Approaches and Maternal-Offspring Complications.Diabetes & metabolism journal · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular disease is the primary cause of mortality in women and men with diabetes. Due to age and worsening of risk factors over the menopausal transition, risk of coronary heart disease events increases in postmenopausal women with diabetes. Randomized studies have conflicted regarding the beneficial impact of estrogen therapy upon intermediate cardiovascular disease markers and events. Therefore, estrogen therapy is not currently recommended for indications other than symptom management. However, for women at low risk of adverse events, estrogen therapy can be used to minimize menopausal symptoms. The risk of adverse events can be estimated using risk engines for the calculation of cardiovascular risk and breast cancer risk in conjunction with screening tools such as mammography. Use of estrogen therapy, statins, and anti-platelet agents can be guided by such calculators particularly for younger women with diabetes. Risk management remains focused upon lifestyle behaviors and achieving optimal levels of cardiovascular risk factors, including lipids, glucose, and blood pressure. Use of pharmacologic therapies to address these risk factors, particularly specific hypoglycemic agents, may provide some additional benefit for risk prevention. The minimal benefit for women with limited life expectancy and risk of complications with intensive therapy should also be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.